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Abstract
Background
The objective of this study was to assess the relationship of pack-years smoking and time
since smoking cessation with risk of lung and heart disease.
Methods
We investigated the history of lung and heart disease in 903 HIV-infected patients who had
undergone thoracic computed tomography (CT) imaging stratified by smoking history. Multi-
morbidity lung and heart disease (MLHD) was defined as the presence of 2 clinical or sub-
clinical lung abnormalities and at least one heart abnormality.
Results
Among 903 patients, 23.7% had never smoked, 28.7% were former smokers and 47.6%
were current smokers. Spirometry indicated chronic obstructive pulmonary disease in
11.4% of patients and MLHD was present in 53.6%. Age, male sex, greater pack-years
smoking history and smoking cessation less than 5 years earlier vs. more than 10 years ear-
lier (OR 2.59, 95% CI 1.27–5.29, p = 0.009) were independently associated with CT
detected subclinical lung and heart disease. Pack-years smoking history was more strongly
associated with MLHD than smoking status (p<0.001).
Conclusions
MLHD is common even among HIV-infected patients who never smoked and pack- years
smoking history is a stronger predictor than current smoking status of MLHD. A detailed
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Introduction
Smoking and HIV infection are independently associated with cardiovascular and respiratory
diseases [1]. Regrettably, the rates of smoking are twofold higher among HIV-infected patients
compared to the general population (42% versus 21%, respectively) and HIV-infected patients
are also less likely to quit smoking (quit ratio, 32.4% vs. 51.7%)[2, 3]. In the Western world, cig-
arette smoking is the single most important modifiable risk factor for preventing lung cancer,
chronic obstructive pulmonary disease (COPD) and coronary heart disease[4, 5]. Among HIV-
infected persons, health hazards of smoking may be greater. For instance, the relative risk of
lung cancer is 3.5 times higher in HIV-infected patients compared with non-infected individu-
als,[6], the prevalence of COPD is increased by approximately 7–21%[7, 8] and cardiovascular
disease (CVD) by 76%[9]. Although mechanisms by which HIV infection enhances the risk of
these conditions are in general unknown, anti-retroviral therapy (ART), immune hyper-activa-
tion and premature senescence have been implicated in the pathogenesis of heart and lung dis-
ease [10].
Despite the importance of smoking in the pathogenesis of lung cancer, COPD, and coronary
artery disease, the impact of cumulative cigarette exposure on the risk of these conditions
among HIV-infected persons has not been well investigated [11]. To date, most published stud-
ies of HIV-infected persons have focused largely on current smoking status, with no or little
attention to cumulative (lifetime) exposure. The primary objective of this study was to deter-
mine the relationship of lifetime smoking history as a measure of cumulative tobacco exposure
and time since smoking cessation with risk of lung and heart disease in a large group of HIV-
infected individuals.
Methods
Study population
This was an observational cross-sectional study of 903 consecutive HIV-infected patients fol-
lowed at the University of Modena HIV metabolic clinic (MHMC) between January 2006 and
September 2012. The details of this cohort have been previously published[12]. In brief,
MHMC is a multidisciplinary centre for the diagnosis and treatment of non-infectious co-mor-
bidities in HIV-infected patients. Patients are assessed (free of charge) for lipodystrophy, diabe-
tes mellitus, hypertension, cardiovascular disease (CVD), osteoporosis, kidney failure, and liver
and lung disease through comprehensive clinical evaluation and a select number of diagnostic
interventions including dual energy X-ray absorptiometry (DEXA), chest and abdominal com-
puted tomography (CT) scans and biochemical blood tests. In 2011 pulmonary function testing
was added as described elsewhere [13]. The current project received approval from the provin-
cial institutional ethics review board at the University of Modena (Comitato Etico Provinciale)
and all subjects provided a written consent to participate in the study.
In the present analysis, we included patients who were older than 18 years, had serologically
documented HIV-1 infection, and had been treated for at least 12 months with ART prior to
enrolment. Exclusion criteria were active lung or heart disease at the time of the enrolment and
pregnancy.
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mass index; CAC, coronary artery calcium; COPD,
chronic obstructive pulmonary disease; CT, computed
tomography; CS, current smokers; CVD,
cardiovascular disease; DEXA, dual energy X-ray
absorptiometry; FEV1, forced expiratory volume in
one second; FRS, Framingham risk score; FS, former
smokers; FVC, forced vital capacity; HDL-C, high-
density lipoprotein cholesterol; HIV, Human
immunodeficiency virus; HOMA-IR, homeostasis
model assessment of insulin resistance; HTN,
hypertension; IQR, interquartile range; LDL-C, low-
density lipoprotein cholesterol; MHMC, Modena HIV
metabolic clinic; MI, myocardial infarction; MLD,
multimorbidity lung disease; MLHD, multimorbidity
lung and heart disease; NRTIs, nucleoside reverse
transcriptase inhibitors; NNRTIs, non- nucleoside
reverse transcriptase inhibitors; NS, never smokers;
PIs, protease inhibitors; PY, pack-years; ROC,
Receiver operating characteristics; T2DM, type 2
diabetes mellitus.
Definition of Clinical Heart and Lung Disease
Clinical lung diseases included COPD and lung cancer diagnosed at the time of patient visit.
We defined COPD using a ratio of post-bronchodilator forced expiratory volume in one sec-
ond to forced vital capacity (FEV1/FVC) of less than 0.70. Pulmonary function tests were per-
formed using a Jaeger Flow Screen spirometer and Jaeger Master Screen plethysmography (RA.
Med srl Medical technology) according to the ATS/ERS recommendations[14], Since spirome-
try was introduced only in 2011, lung function parameters were available in 39% of the cohort.
Lung cancer was defined based on standard histology. In this cohort, lung cancer was
detected through the use of screening CT scans.
Clinical heart disease was defined as myocardial infarction (MI), which was diagnosed
based on MONICA criteria, [15] by patient history or by detection of an area of myocardial
scarring on cardiac CT scans at the time of the patient visit.
Definition of Subclinical Heart and Lung Disease
Subclinical lung and heart conditions were detected with CT imaging. For this purpose, a cra-
nio-caudal sequence of 30–40 consecutive axial slices of the heart was acquired with a 64-slice
volume CT multidetector scanner (GE Medical Systems, Milwaukee, WI). All images were
obtained during a single breath hold using 320 mAs and 140 Kv. Image acquisition was pro-
spectively triggered at 80% of the R-R interval on the surface electrocardiogram. A section
thickness of 2.5 mm, a field of view of 20 cm2, and a matrix of 512 x 512 were used to recon-
struct the raw image data, yielding a nominal pixel size of 0.39 mm2 and a voxel of 0.4 mm3.
CT Images were evaluated for findings of pulmonary emphysema, and bronchiolitis as
defined by the Fleischner Society glossary of terms by 3 radiologists by consensus reading
using an offline CT workstation (AW 4.4, GE Healthcare, Milwaukee, WI). [16]. Subclinical
lung conditions were detected based on semi-quantitative scores for emphysema (i), bronchiol-
itis (ii), bronchial wall thickening (iii), bronchiectasis (iv) and non-calcified lung nodules (v)
[17].
Subclinical coronary vascular abnormality was assessed with coronary artery calcium
(CAC). CAC was quantified according to the Agatston technique [18]. A CAC score cut off
>100 was considered evidence of significant coronary artery disease risk, as this threshold has
been shown to correlate closely with adverse cardiac events in the general population.
Multimorbidity lung and heart disease
Multimorbidity lung and heart disease (MLHD) was defined by the presence of 2 clinical or
subclinical lung abnormalities and at least one cardiovascular condition (either CAC>100 or
previous myocardial infarction). This composite end-point was used to capture the impact of
cigarette smoking on the complex interaction of heart and lung diseases (both clinical and
subclinical).
Smoking history
Smoking information was collected for all patients, including current smoking status, duration,
intensity of smoking during different life periods, time since cessation and age at smoking initi-
ation. The pack-years of smoking were calculated by multiplying the average number of packs
of cigarettes smoked per day (intensity) by the number of years the person had smoked. Pack-
years smoking history estimates the lifetime exposure to tobacco. Smoking status was classified
into 3 groups: never smoked, former smoker and current smoker.
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To determine the impact of smoking, the study cohort was subdivided into 7 groups: never
smokers (NS), former smokers with a pack-years history10 (FS<10PY), former smokers
with a pack-years history of 11–20 (FS:11–20PY), former smokers with a pack-years history
>20 (FS>20PY), current smokers with a pack-years history10 (CS<10PY), current smokers
with a pack-years history of 11–20 (CS:11–20PY), and current smokers with a pack-years his-
tory>20 (CS>20PY). In the former smoker category, time since smoking cessation was cate-
gorized into 3 groups:<5 years, 5–10 years,>10 years of quitting. Information regarding use
of illicit intravenous drugs was also collected.
Covariates
Demographic and clinical data at the time of CT scanning were captured. HIV related variables
were collected by patient medical chart review and included: nadir and current CD4+ T lym-
phocyte cell count/mm3 (CD4), time since HIV diagnosis and cumulative exposure to antire-
troviral drugs: protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs)
and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Efficacy of ART was deter-
mined by measuring plasma HIV-1 RNA at the time of CT scan and dichotomized as below or
above the limit of detection (<40 c/mL). Previous AIDS diagnosis was defined according to the
Centers for Disease Control group “C” category[19]. Anthropometric measurements were:
waist circumference, body mass index (BMI, calculated as weight in kilograms divided by the
square of height in meters). Lipodystrophy was defined according to the HOPS categories [20].
Metabolic variables were collected following an overnight fast. The measured serum lipids
included total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein choles-
terol, and triglycerides. Insulin resistance was calculated using the homeostasis model assess-
ment equation: HOMA-IR 1/4 [fasting insulin (mU/ml) x fasting glucose (mmol/l)/22.5]. The
Framingham risk score (FRS) was calculated for each patient using equations developed by the
Adult Treatment Panel III[21].
Statistical Analyses
Patient characteristics were compared among groups using ANOVA and Kruskal-Wallis test
for continuous normally distributed and non-normally distributed variables, respectively. Fish-
er’s exact test was used to compare categorical variables. The prevalence of clinical and subclin-
ical manifestations was compared among groups using a Fisher’s exact test: post-hoc analyses
were performed using Bonferroni adjustments. Trends in prevalence of pulmonary and cardio-
vascular diseases were tested using Cochran–Armitage test. Factors associated with MHLD
were assessed using univariate and multivariable logistic regression analyses. Covariates
included in the final model were: age, sex, HOMA-IR, HIV transmission route, and smoking
history. Receiver operating characteristics (ROC) analyses were used to compare the associa-
tion between disease states (lung, heart, and MLHD) and current smoking status or pack-years
of smoking. C-statistics were used to compare the ROC curves of various models. Statistical sig-
nificance level was set at p<0.05 (two-tailed). All statistical analyses were performed using
STATA 13.1 for Mac (StataCorp, College Station, TX, US).
Results
Participants
Of the 903 participants, 263 (29%) were women and 99% were Caucasians. The mean patient
age (SD) was 48 years (SD 7.5). Anthropometric, laboratory values and lifestyle characteristics
are described in Table 1. There were 214 patients (23.7%) who had never smoked, 259 (28.7%)
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were former smokers and 430 (47.6%) were current smokers. Pack-years of smoking were
greater in current than in former smokers (median 22.5 pack-years versus 14.0 pack-years;
p<0.001). Using our smoking categories 214 (23.7%) patients were NS, 102 (11.3%) FS<10PY,
63 (7.0%) FS:11–20PY, 94 (10.4%) FS>20PY, 60 (6.6%) CS<10PY, 120 (13.3%) CS:11–20PY,
and 250 (27.7%) CS>20PY.
Respiratory diseases
Three lung nodules (0.3%) suspicious of carcinoma were found on CT imaging. Histological
examination confirmed the diagnosis of lung cancer in all 3 patients. Of the 350 patients who
underwent pulmonary function testing, 40 (11.4%) were diagnosed with COPD. Among these
patients, 28 had emphysema on CT imaging. Among the 12 patients without emphysema, 10
Table 1. Demographic and clinical characteristics of the study group by smoking status.
Never smoker (n = 214) Former smoker (n = 259) Current smoker (n = 430) p
Women, n (%) 59 (27.6%) 79 (30.50) 125 (29.07) 0.789
Age, mean (sd) 48.44 (8.72) * 50.16 (7.41) ^ 47.92 (6.50) *^ <0.001
Sedentary life, n (%) 103 (49.28) * 128 (50.59) ^ 246 (58.99) *^ 0.002
Alcohol <20 g/day, n (%) 60 (28.71) *^ 103 (40.71)^ 188 (45.08) * <0.001
Waist circumference, mean, cm (sd) 88.88 (10.48) * 88.37 (9.50) *^ 85.84 (9.15) *^ <0.001
BMI, mean (sd) 24.52 (3.87) * 24.07 (3.29) *^ 23.15 (3.77) ^ <0.001
Lipodystrophy 0.013
Lipoatrophy, n (%) 52 (33.77) * 70 (40.94) 138 (47.59) *
Lipohypertrophy, n (%) 17 (11.04) 18 (10.53) 18 (6.21)
Mixed form, n (%) 55 (35.71) * 61 (35.67) 76 (26.21) *
Fasting glucose, mg/dL, mean (sd) 97.41 (20.30) 100.94 (25.90) * 94.82 (23.65) * 0.005
HOMA-IR, median (IQR) 2.24 (1.46–3.78) * 2.61 (1.68–4.43) ^ 1.81 (1.17–3.12) *^ <0.001
Triglycerides, mg/dL, median (IQR) 148.5 (105–220) 147 (98–209) 147 (106.5–213.5) 0.789
Total Cholesterol, mg/dL, mean (sd) 199.74 (47.24) 198.20 (47.00) 194.50 (41.21) 0.327
HDL-C, mg/dL, mean (sd) 47.90 (15.35) 49.20 (15.25) ^ 45.29 (13.73) ^ 0.002
LDL-C, mg/dL, mean (sd) 120.17 (36.83) 117.90 (35.64) 117.51 (34.30) 0.671
CD4 Nadir, cells/microL, median (IQR) 188.5 (76–292) * 141 (45–250) *^ 187.5 (82–280) ^ 0.002
Current CD4, cells/microL median (IQR) 575 (437–713) 527 (413–703) * 594 (441–824) * 0.037
Cumulative exposure to NRTIs, months, median (IQR) 118 (68–153) * 138 (94–181) * 131 (69–171) 0.030
Cumulative exposure to PIs, months, median (IQR) 50 (8–81) 51 (22–91) 59 (19–99) 0.556
Cumulative exposure to NNRTIs, months, median (IQR) 28 (3–66) 23 (0–71) 23 (0.61) 0.602
HTN, n (%) 86 (40.19) 121 (46.72) ^ 147 (34.19) ^ 0.005
T2DM, n (%) 32 (14.95) 48 (18.53) ^ 44 (10.23) ^ 0.008
FRS, median (IQR) 3 (1–7) * 4 (1–7) ^ 7 (3–12) *^ <0.001
Age of smoking initiation 16 (15–18) 16 (15–18) 0.921
Pack-Years, median (IQR) 0 (0) 14 (7–26.25) 22.5 (14.6–30.6) <0.001
0–10 PY, n (%) 102 (39.38) 60 (13.95)
11–20 PY, n (%) 63 (24.32) 120 (27.91)
>20 PY, n (%) 94 (36.29) 250 (58.14)
BMI- body mass index; FRS- Framingham Risk Score; HDL-C- high-density lipoprotein cholesterol; HOMA-IR- homeostasis model assessment of insulin
resistance; HTN- hypertension; IQR- interquartile range; LDL-C- low-density lipoprotein cholesterol; NNRTIs- non-nucleoside reverse-transcriptase
inhibitors; NRTIs- nucleoside reverse transcriptase inhibitors; PIs- protease inhibitors; PY- pack-years; sd- standard deviation; T2DM- type 2 diabetes
mellitus. Symbols (* and ^) represent statistical signiﬁcant differences between groups in the same line. If two cells in the same line have the same
symbol means that that comparison is statistically signiﬁcant.
doi:10.1371/journal.pone.0143700.t001
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had CT evidence of bronchial wall thickening. Among the 860 patients without clinical COPD
and/or lung cancer, CT scanning identified the following pulmonary conditions: 296 patients
(34.4%) had emphysema, 254 (29.5%) had bronchiolitis, 38 (4.4%) had non-calcified lung nod-
ules, 528 (61.4%) had significant bronchial wall thickening and 139 (16.2%) had bronchiectasis.
Multimorbidity lung disease (MLD) was found in 410 (47.7%) patients. The distribution of
clinical, subclinical and multimorbidity lung disease by smoking status and pack-year groups is
shown in Figs 1, 2 and 3 respectively. There was a trend towards a higher risk of clinical, sub-
clinical and multimorbidity lung disease with increasing pack-years of smoking. The highest
prevalence was found in current smokers.
Cardiovascular disease
Forty-three patients (4.7%) had evidence of prior myocardial infarction (MI): 30 (3.3%) had a
clinical history of MI and 13 (1.4%) demonstrated areas of myocardial scarring on CT imaging.
By smoking status, 8 MIs occurred in never smokers, 22 in former smokers and 13 in current
Fig 1. Prevalence of clinical lung diseases by smoking status and pack-years groups. The letters represent each group and when placed on the top of
a bar it represents a statistical difference between that bar and the group the letter represent.
doi:10.1371/journal.pone.0143700.g001
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Fig 2. Prevalence of subclinical lung conditions by smoking status and pack-years groups. The letters represent each group and when placed on the
top of a bar it represents a statistical difference between that bar and the group the letter represent.
doi:10.1371/journal.pone.0143700.g002
Fig 3. Prevalence of multimorbidity lung diseases by smoking status and pack-years groups. The letters represent each group and when placed on
the top of a bar it represents a statistical difference between that bar and the group the letter represent.
doi:10.1371/journal.pone.0143700.g003
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smokers. Of note 8 patients among the former smokers were active smokers at the date of the
myocardial event. CAC>100 was found in 90 (10%) patients; 16 (7.5%) among never smokers,
30 (11.5%) among former smokers and 44 (10.2%) among current smokers. One-hundred
twenty-three (13.6%) patients had CAC>100 and/or previous MI. Distribution of MIs by
smoking status and pack-years category is shown in Fig 4. There was a trend toward a higher
prevalence of clinical and subclinical heart disease with increasing pack-years of smoking, both
in former (p<0.001) and in current smokers (p<0.001). The highest prevalence was found in
current smokers.
MLHD
MLHD was present in 484 (53.6%) patients: 78 (36.5%) were never smokers (Fig 5). There was
a trend towards a higher prevalence of MLHD with increasing pack-years of smoking, both in
former (p<0.001) and in current smokers (p<0.001). The highest prevalence was observed in
current smokers. Fig 6 shows the interaction of smoking status with pack-years for the risk of
MLHD.
Fig 4. Prevalence of clinical and subclinical heart diseases by smoking and pack-years groups.
doi:10.1371/journal.pone.0143700.g004
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Multivariarble and ROC analyses
Amultivariable logistic regression model (Fig 7) was built to identify independent predictors
of MLHD. Variables independently associated with MLHD were: age per 10-years interval
increase (OR = 2.15, 95% CI:1.71–2.69), male gender (OR = 1.62, 95% CI:1.16–2.26) and
FS>20PY (OR = 2.02, 95% CI:1.17–3.49), CS:11–20PY (OR = 2.44, 95% CI:1.47–4.03) and
CS>20PY (OR = 5.37, 95% CI:3.39–8.51).
ROC curves were used to assess how well pack-years and smoking status predicted clinical
and subclinical lung disease (Fig 8 - panel A), clinical and subclinical heart disease (Fig 8 -
panel B), and MHLD (Fig 8 - panel C). Pack-years were more closely associated with clinical
and subclinical MLHD than smoking status (p<0.001).
We also evaluated whether smoking cessation modified the risk of MLHD among 259 for-
mer smokers. In this group, time since smoking cessation was<5 years in 46 (18%) patients,
5–10 years in 59 (23%) patients, and>10 years in 154 (59%) patients. In these 3 groups, the
prevalence of MLHD was 61%, 46%, and 46%, respectively (p = 0.188). After adjustment for
age and sex, independent predictors of MLHD were current smoking (OR 3.14, 95% CI 2.07;
Fig 5. Prevalence of MLHD by smoking and pack-years groups.
doi:10.1371/journal.pone.0143700.g005
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Fig 6. Probability of MLDH by pack-years in former and current smokers: Univariate logistic
regression.
doi:10.1371/journal.pone.0143700.g006
Fig 7. Factors associated with MLHD: Multivariable logistic regression.
doi:10.1371/journal.pone.0143700.g007
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4.75, p<0.001) and smoking cessation less than 5 years prior (OR 2.59, 95% CI 1.27; 5.29,
p = 0.009) (Fig 9). We tested the interaction between smoking cessation and pack-years; only
smoking cessation time<5 years among patients with>10 pack-years was a significant risk
factor for MLHD (Fig 10).
Discussion
In this well-characterized and prospectively followed cohort of HIV-infected patients we
observed that lifetime cumulative cigarette smoking exposure was a significant and powerful
predictor of clinical and subclinical cardio-pulmonary disease. We observed a high rate of
Fig 8. Sensitivity and specificity of pack-years and smoking status in predicting clinical and subclinical lung and heart diseases. ROC curves for
sensitivity and specificity of pack-years and smoking status in clinical and subclinical lung disease (A), clinical and subclinical heart disease (B), and MHLD
(C).
doi:10.1371/journal.pone.0143700.g008
Fig 9. MLHD and time since smoking cessation.Multivariable logistic regression.
doi:10.1371/journal.pone.0143700.g009
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current smoking and, as expected in this patient group, a very high burden of pulmonary and
cardiac disease. In contrast, current smoking status performed quite poorly in predicting
MLHD, suggesting that ascertaining only current smoking status, which has been the case in
previous epidemiological studies, may underestimate the true adverse cardio-pulmonary
impact of smoking among HIV-infected patients. Additionally, prior smoking was indepen-
dently associated with a high prevalence of clinical and subclinical disease. Therefore, our data
suggest that smoking pack-year history should be routinely collected in clinical and epidemio-
logic studies seeking to assess the health impact of tobacco use, and also highlight the impor-
tance of smoking cessation in mitigating the risk of heart and lung disease among HIV infected
individuals.
Our findings corroborate those of Petoumenos et al, who showed that the risk of cardiovas-
cular disease decreases with increasing time since smoking cessation among HIV-infected
patients[22]. Our data complement and extend those findings by demonstrating that the risk
of MLHD is significantly reduced after 5 years or more of smoking cessation among patients
with less than 10 pack-years of smoking (Fig 10). In patients with greater cumulative cigarette
exposure, the time required to achieve smoking cessation benefits may be longer.
However, these data should be interpreted with caution since we could not ascertain
whether smoking cessation for some patients occurred as a consequence of medical illness as
opposed to a voluntary decision. Indeed, previous studies have suggested that some smokers
quit because of an acute smoking-related medical event, leading to a bias that is commonly
referred to as an “ill-quitter effect”[23]. This phenomenon may spuriously elevate the apparent
risk of smoking-related morbidity and mortality among former smokers during the early years
following smoking cessation. There were additional limitations to our analyses; because of the
observational nature of the study, there could have been a survival bias. Given that pack-year
data are calculated from patient self-reporting, we cannot exclude patient bias. We also did not
collect data regarding environmental tobacco smoke in non-smokers, or occupational exposure
to smoke, air pollution and other cardio-pulmonary risk factors in smokers and non-smokers.
Moreover, we performed pulmonary function tests in only 350 patients (38.7%) and data
regarding recreational drugs was not comprehensive; our questionnaires included only infor-
mation about cocaine and heroin use and not other illicit drugs such as cannabis. Finally, we
Fig 10. MLHD and time since smoking cessation.Multivariable logistic regression in (A) former smokers with less than 10 pack-years and (B) more than
10 pack-years smoking history.
doi:10.1371/journal.pone.0143700.g010
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did not have available for comparison a control group of HIV-uninfected patients to allow
cross-comparisons.
Nevertheless, our findings are important for the following reasons: first, obtaining pack-
year history of smoking is important for both former and current smokers, when assessing risk
of clinical and subclinical heart and lung disease. Second, careful assessment of pack-year his-
tory of smoking may enable cost-effective screening for clinical and subclinical lung and heart
disease among HIV-infected individuals. Third, smoking cessation strategies may be most
effective among patients with shorter pack-year history of smoking.
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